Bone Biologics Corp (NASDAQ:BBLG) — Market Cap & Net Worth
Market Cap & Net Worth: Bone Biologics Corp (BBLG)
Bone Biologics Corp (NASDAQ:BBLG) has a market capitalization of $1.49 Million ($1.49 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30385 globally and #6183 in its home market, demonstrating a -1.82% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bone Biologics Corp's stock price $0.54 by its total outstanding shares 2756057 (2.76 Million). Also see BBLG asset base for a full breakdown of the balance sheet.
Bone Biologics Corp Market Cap History: 2016 to 2026
Bone Biologics Corp's market capitalization history from 2016 to 2026. Data shows change from $66.15 Billion to $1.49 Million (-64.13% CAGR). Also see BBLG cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Bone Biologics Corp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #894 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #2841 of 3165 |
Weight: Bone Biologics Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Bone Biologics Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bone Biologics Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Bone Biologics Corp stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BBLG by Market Capitalization
Companies near Bone Biologics Corp in the global market cap rankings as of September 18, 2026. Review BBLG tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Bone Biologics Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Bone Biologics Corp Historical Marketcap From 2016 to 2026
Between 2016 and today, Bone Biologics Corp's market cap moved from $66.15 Billion to $ 1.49 Million, with a yearly change of -64.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.49 Million | -62.76% |
| 2025 | $4.00 Million | +54.21% |
| 2024 | $2.59 Million | -79.20% |
| 2023 | $12.46 Million | -91.02% |
| 2022 | $138.71 Million | -94.04% |
| 2021 | $2.33 Billion | -81.23% |
| 2020 | $12.40 Billion | +87.50% |
| 2019 | $6.61 Billion | -84.62% |
| 2018 | $42.99 Billion | +15.56% |
| 2017 | $37.21 Billion | -43.75% |
| 2016 | $66.15 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Bone Biologics Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.49 Million USD |
| MoneyControl | $1.49 Million USD |
| MarketWatch | $1.49 Million USD |
| marketcap.company | $1.49 Million USD |
| Reuters | $1.49 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bone Biologics Corp
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, a… Read more